Clinical Trial Update: Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis [Phase 2, Phase 3]

View source ↗

Summary

This document reports an ongoing Phase 2/Phase 3 clinical trial evaluating sirolimus for preventing post-COVID fibrosis in patients with COVID-19 pneumonia. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-acute Sequelae of Sars-cov-2 Infection
• Pulmonary Fibrosis

Drugs mentioned

• Rapamune (sirolimus) (sirolimus)

Snippet

Sponsor: University of Chicago | Conditions: Pulmonary Fibrosis, COVID-19 Pneumonia | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING